Binnie, Lauren R.
Pauls, Mathilde M. H.
Benjamin, Philip
Dhillon, Mohani-Preet K.
Betteridge, Shai
Clarke, Brian
Ghatala, Rita
Hainsworth, Fearghal A. H.
Howe, Franklyn A.
Khan, Usman
Kruuse, Christina
Madigan, Jeremy B.
Moynihan, Barry
Patel, Bhavini
Pereira, Anthony C.
Rostrup, Egill
Shtaya, Anan B. Y.
Spilling, Catherine A.
Trippier, Sarah
Williams, Rebecca
Isaacs, Jeremy D.
Barrick, Thomas R.
Hainsworth, Atticus H. http://orcid.org/0000-0001-7877-8013
Funding for this research was provided by:
alzheimer's drug discovery foundation (20140901)
uk alzheimer society (20140901)
national institute for health research (CL-2015-16-001)
Article History
Received: 28 July 2021
Revised: 15 December 2021
Accepted: 22 December 2021
First Online: 26 January 2022
Declarations
:
: LRB and MMHP were employed as part of the PASTIS trial, JDI was Principal Investigator, and AHH was Chief Investigator. CK is a PI on clinical trials with Bristol-Myers-Squibb and Bayer and has received funding from Novo Nordisk, Bayer and Bristol-Myers-Squibb, all not relevant to the present trial. JDI has been a PI on clinical trials funded by Roche, Merck and Lupin Pharmaceuticals and has received funds from Biogen and Roche, none relevant to the present trial. AHH has received honoraria from Eli-Lilly and from NIA, he chairs the Vascular Cognitive Disorders PIA within ISTAART, and he leads MRC-Dementias Platform UK Vascular Experimental Medicine group. All other authors report no relevant disclosures.
: The trial received ethical approval from the UK National Research Ethics Service (London-Brent research ethics committee, REC reference: 15/LO/0714).
: Not applicable.
: Written informed consent was obtained from all participants or their next of kin.
: This paper contains no images of participants and no other identifiable participant data.